摘要
免疫检查点抑制剂可持续诱导免疫反应,但抗体大分子本身存在缺陷,对免疫抑制细胞的忽视使其仅对一小部分肿瘤患者有效.二代免疫检查点抑制剂包括结合Fcγ受体的抗程序性死亡受体（PD）-1/PD配体1（PD-L1）抗体、双免疫检查点抗体、小分子免疫检查点抑制剂和PD-1/PD-L1抗体耦联药物,其克服了一代抗PD-1/PD-L1抗体的不足,将成为未来免疫治疗的新方向.
Immune checkpoint blockades can induce long lasting responses but only in a fraction of patients owing to deficient of antibody as well as the neglect of immune suppressive cells.Next-generation immune checkpoint blockades,including FcγR-binding anti-programmed cell death-1 （PD-1）/PD ligand 1 （PD-L1） antibodies,co-inhibitors of immune checkpoint,small-molecule modulators and antibody-drugs conjugated with PD-1/PD-L1,will overcome the deficiencies of current anti-PD-1/PD-L1 antibodies and will become the direction of immunotherapy in the future.
作者
张百红
岳红云
Zhang Baihong;Yue Hongyun(Department of Oncology, Lanzhou General Hospital of Lanzhou Military Region, Lanzhou 730050, Chin)
出处
《国际肿瘤学杂志》
CAS
2018年第4期238-240,共3页
Journal of International Oncology
基金
甘肃省自然科学基金（1308RJZA181）
